Ellis has secured marketing approval for Furmonertinib Mesylate Tablets, a groundbreaking medication tailored to treat adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations. Prior to this milestone, the drug was prioritized for review by the Center for Drug Evaluation (CDE) and had entered the conditional approval phase. As a third-generation EGFR-TKI, Furmonertinib has already been authorized for both second-line and first-line therapy of EGFR mutations and is included in the national medical insurance catalog. Currently, Furmonertinib is advancing through global multicenter Phase III clinical trials specifically targeting EGFR exon 20 insertion mutations, and it has garnered Breakthrough Therapy Designation from regulatory bodies in both China and the United States. Additionally, clinical investigations of the drug for various other NSCLC-related indications are actively progressing.